BURLINGTON, Mass., Oct. 17, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the hospital-treated MRSA (HT-MRSA) drug market will grow modestly over the next decade from approximately $900 million in 2012 to $1 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor advisory service report entitled Methicillin-Resistant Staphylococcus Aureus finds that as many as eight new agents with activity against MRSA are forecasted to launch within the next ten years. Among these agents, Cubist's second-generation IV/oral oxazolidinone, tedizolid, is best positioned for commercial success due to its high efficacy against MRSA, convenient once-daily dosing and its ability to achieve clinical cure with a shorter course of therapy compared to Pfizer's Zyvox/Zyvoxid (linezolid).
While the uptake of tedizolid for HT-MRSA infections will help drive growth in this market, the entry of generic formulations of current market share leading therapies—Zyvox/Zyvoxid and Cubist/Novartis/Merck's Cubicin (daptomycin)—will constrain growth. In 2012, Zyvox/Zyvoxid and Cubicin sales accounted for 70 percent of HT-MRSA major-market sales—however, due to aggressive generic erosion, by 2022 sales of these therapies will comprise just 40 percent of the HT-MRSA market.
The findings also reveal that the HT-MRSA market is becoming increasingly crowded, particularly as the majority of emerging therapies target the complicated skin and skin structure infection segment of this market. As a result, new agents will need to clearly differentiate themselves from current and emerging therapies by targeting underserved indications, such as nosocomial pneumonia and bloodstream infections, in order to find favorable uptake and formulary positioning in this competitive market. Additionally, hospitals are seeking to contain healthcare costs by transitioning patients towards early hospital discharge. This practice will drive uptake of agents with IV and oral formulations that permit step-down therapy (such as Nabriva's BC-3781, Tetraphase's eravacycline, Melinta's delafloxacin and tedizolid), as well as IV agents with once-weekly dosing schemes (such as Durata's dalbavancin and The Medicines Company's oritavancin).
"As physicians are increasingly required to provide a high standard of care in a cost-effective manner, the HT-MRSA market is primed for new therapies that can reduce the length of hospitalization," said Decision Resources Analyst Maria Ascano, Ph.D. "Early hospital discharge not only reduces costs but also diminishes the likelihood of transmission or colonization of a patient with a nosocomial pathogen. Both oral antibiotics and IV antibiotics that are convenient for outpatient parenteral antibiotic therapy can facilitate early discharge by allowing patients to complete their therapy in the outpatient setting, ultimately reducing hospitalization costs."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.
SOURCE Decision Resources